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Background: Despite major advances in treating patients with severe heart
failure, deciding who should receive an implantable cardiac defibrillator (ICD)
remains challenging.
Objective: To study the risk factors and mortality in patients after receiving an ICD
(January 2008–December 2015) in a regional hospital in Australia.
Methods: Eighty-two primary prevention patients received an ICD for ischemic
cardiomyopathy (ICM, n = 41) and non-ischemic cardiomyopathy (NICM, n = 40) with
4.8-yrs follow-up. One patient had mixed ICM/NICM indications. Ventricular arrhythmias
were assessed using intracardiac electrograms. Statistical analysis compared the total
population and ICM and NICM groups using Kaplan-Meier for survival, Cox regression
for mortality predictors, and binary logistic regression for predictors of ventricular
arrhythmias (p < 0.05).
Results: Major risk factors were hypercholesterolemia (70.7%), hypertension (47.6%),
and obesity (41.5%). Severe obstructive sleep apnea (OSA) was found exclusively in
NICM patients (23.7%, p = 0.001). Mortality was 30.5% after 4.8-yrs. The majority of
patients (n=67) had no sustained ventricular arrhythmias yet 28% received therapy (n
= 23), 18.51% were appropriate (n = 15), and 13.9% inappropriate (n = 11). Patients
receiving ≥2 incidences of inappropriate shocks were 18-times more likely to die (p =
0.013). Three sudden cardiac deaths (SCD) (3.7%) were prevented by the ICD.
Conclusion: Patients implanted with an ICD in Townsville had 30.5% all-cause mortality
after 4.8-yrs. Only 28% of patients received ICD therapy and 13.9% were inappropriate.
OSA may have contributed to the fourfold increase in inappropriate therapy in NICM
patients. Our study raises important efficacy, ethical and healthcare cost questions about
who should receive an ICD, and possible regional and urban center disparities.
Keywords: heart failure, implantable cardiac defibrillator, primary prevention, arrhythmia, sudden cardiac death,
shocks
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INTRODUCTION
Heart failure (HF) represents a global healthcare pandemic that
affects over 26 million people worldwide including 5.8 million in
the United States, 10 million in Europe, up to 9 million in South
East Asia, and around 300,000 in Australia (1–4). Despite major
advances in patient management and drug therapies, treating
patients with severe HF remains challenging. The problem is
formidable given that 30–50% of this group will experience a
cardiac arrest (5), which has an out-of-hospital survival rate of
<10% (3, 5). To address this problem, 40 years ago Mirowski and
colleagues were among the first to introduce implantable cardiac
defibrillators (ICDs) into cardiac arrest patients as a preventive
measure to reduce further attacks (6), which has now become a
global standard practice in developed countries (7, 8).
Today, ICDs are also recommended for primary prevention
patients with ischemic cardiomyopathy (ICM), usually from a
previous myocardial infarction, and patients with non-ischemic
cardiomyopathy (NICM) of a dilated or non-dilated origin with
a left ventricular ejection fraction (LVEF) ≤35% (3, 5, 9, 10).
ICM is the most common type of dilated cardiomyopathy where
the left ventricle has been enlarged, dilated, and weakened
usually from ischemia associated with coronary artery disease
and myocardial infarction. NICM is defined as disease of the
myocardium associated withmechanical or electrical dysfunction
from ventricular hypertrophy or dilatation with a strong genetic
component (3, 10, 11).
Notwithstanding the small clinical risks of device insertion
(12), the most common problems of the ICD include lead failure,
premature battery life, failure of algorithms to discriminate
ventricular from supraventricular arrhythmias, device activation
when shocks are not required, and patient anxiety issues (e.g.,
anticipatory “phantom shocks”) (8, 13). Despite the potential
of ICDs to save lives, there is increasing controversy about
who should receive a device, and their clinical efficacy (8,
14). Differences in patient outcomes appear to reflect the
complexity of multiple phenotypes of heart failure with different
comorbidities, the selection criteria based on ejection fraction
classification, and lack of consensus guidelines for patient
selection (4, 8, 13, 15). The aim of this study was to define
risk factors, arrhythmia incidence, and mortality in primary
prevention heart failure patients in the Townsville district in
northern Australia. Secondary objectives were to investigate
differences between ICM and NICM patients, and to compare
findings with published data from larger metropolitan centers.
This is, to the best of our knowledge, the first such analysis of
ICD patients in regional Australia.
MATERIALS AND METHODS
Ethical Considerations
This study was conducted in full conformance with the
principles of the National Statement on Ethical Conduct in
Human Research (Updated 2018). The study was approved by
the Townsville Hospital and Health Service (THHS) Human
Research Ethics Committee (HREC) (HREC/18/QTHS/57) and
James Cook University HREC (H7438).
Study Population
The study population consisted of 82 patients within the THHS
District who had a primary prevention ICD implanted at
Townsville University Hospital (TUH) between January 1st, 2008
and December 31st, 2015. The study population included new
implants and generator changes, which in a few cases required
a device history prior to 2008. Primary prevention ICD generator
changes were included as this reflects normal clinical practice.
Primary prevention patients who had an ICM or NICM
indication were included for analysis, while all secondary
prevention ICD patients were excluded. Angiography was used to
exclude coronary artery disease as a cause of cardiomyopathy in
NICM patients. All patients had coronary angiography with the
exception of five patients who had a genetic or familial indication
for ICD, e.g., long QT syndrome, non-compaction, sarcoidosis.
In order to reduce the heterogeneity of non-ischemic group we
identified and separated channelopathy patients with preserved
ejection fraction. Exclusion criteria included incomplete chart
information or ICD follow-up data. Patients were identified as
indicated by implant report or clinic letter by the implanting
Cardiac Electrophysiologist. Primary prevention indications
were those with a history of coronary artery disease (CAD)
or myocardial infarction, or the absence of CAD with an
LVEF ≤35% on maximal medical therapy and New York Heart
Association (NYHA) functional class II-III, or NYHA class 1
and an LVEF ≤30%. There was no prior history of sustained
ventricular arrhythmias subsequent to ICD implantation in this
patient cohort.
Data Collection and Analyses
Data were retrospectively collected from TUH’s medical
records and Cardiobase (version 8.1) from which clinic
letters and ICD follow-up information was obtained (Public
Health Act Approval: RD007511). Demographic information,
comorbidities, ejection fraction (EF), and medications prior to
ICD implantation were extracted and recorded. Obesity status
was indicated by clinic letter or with a body mass index (BMI)
≥30. New implant device follow-up information, including
complications and all-cause mortality, was collected from time of
implant up until December 31st, 2018. For patients who received
an ICD generator change, follow-up details were included from
the previous devices to obtain a complete ICD history.
Device Settings
All devices were programmed at the discretion of the implanting
cardiac electrophysiologist and had atrial arrhythmia algorithms
turned on. Subcutaneous ICDs had a shock zone from 220–
240 bpm and a conditional shock zone from 180–200 bpm with
full output shocks programmed. Devices from Boston Scientific,
Abbott, and Biotronik predominantly had a two-zone active
therapy configuration with a monitor zone, whereas Medtronic
devices mostly had three active therapy zones and amonitor zone
programmed. Examples of short, intermediate, and long duration
detection endocardial device settings can be found in Table 1.
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TABLE 1 | Endocardial device detection settings.
Duration VF zone FVT zone Third active zone*
VT zone Monitor zone











ATP while charging 2–10 ATP 6–8 ATP No therapy
Max shocks Max shocks Max shocks










ATP while charging 1–10 ATP 2–8 ATP No therapy
Max shocks Max shocks Max shocks











ATP while charging 2–8 ATP 2–8 ATP No therapy
Max shocks Max shocks Max shocks
*If programmed. VF, ventricular fibrillation; FVT, fast ventricular tachycardia; VT, ventricular tachycardia; ATP, antitachycardia pacing therapy.
Interpretation of ICD Therapy
Therapy was deemed “appropriate” for ventricular arrhythmias
or “inappropriate” for supraventricular arrhythmias or device
and/or lead malfunction. The terms “therapy” in this study refer
to anti-tachycardia pacing (ATP) and shocks, and “shocks” refer
to defibrillation from the ICD. Interpretation of therapy occurred
in one of two ways: (1) From electrocardiograms in the clinical
letters, which were interpreted by a certified cardiac device
specialist (CCDS) and checked by a consultant medical specialist
(KN), or (2) from individual device intracardiac electrograms
of patients that were not found in the clinical letters, and
interpreted by the same investigators (CCDS and KN). Single
chamber devices were interpreted using onset and stability as
well as electrogram morphology match score. When this was
not optioned on the device the high voltage electrogram (far
field) was analyzed for changes during onset and offset to
identify changes to distinguish supraventricular tachycardia from
ventricular tachycardia. For dual chamber devices ventricular
tachycardia was identified by ventricular electrogram rate greater
than atrial electrogram rate (V>A). When tachycardia was
1:1, the chamber of tachycardia onset was used together with
onset (gradual or sudden) and stability (regular or irregular).
Electrogram morphology was also used as a discriminator.
As for single chamber devices, if unavailable the high voltage
electrogram was assessed to differentiate supraventricular from
ventricular tachycardia.
Sudden Cardiac Death Criteria
Sudden cardiac death was defined as spontaneously occurring
ventricular tachycardia or ventricular fibrillation >240 beats
per minute based on published work (16). If ventricular
tachycardia was caused by anti-tachycardia pacing leading to
an acceleration of heart rate >240 it was excluded from our
criteria of sudden cardiac death. ICD intracardiac electrograms
were assessed to identify patients who met this criterion in
our study. This criterion relates to arrhythmic death only
and does not account for all cases of sudden death that may
also have occurred from non-arrhythmogenic pump failure
because of the severely reduced LVEF found in this patient
population (16).
Statistical Analysis
Statistical analysis was conducted using IBM SPSS version
24. Descriptive analysis is reported as frequencies, mean
(standard deviation) or median (interquartile range). Variables
were compared within the total population, and between
ICM and NICM patients with Chi-squared test for categorical
data and analysis of variance (ANOVA) with Levene’s test
of homogeneity of variance for continuous variables. One
patient had a mixed indication for ICD and was not included
in ICM vs NICM analysis. Kaplan–Meier test was used for
survival analysis, with log-rank test for comparison between
ICM and NICM patients. Cox proportional hazard analysis was
performed to determine predictors of mortality, and binary
logistic regression was used to assess associations between patient
variables and appropriate ICD therapy. Multivariate regression
analysis was conducted for parameters showing statistical
significance in univariate tests. A p < 0.05 was considered
statistically significant.
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TABLE 2 | Demographics and risk factors of primary prevention heart failure patients.
Parameter Total population ICM NICM P-value
Age (yrs) 59 ± 16 62 ± 12 55 ± 18 0.045
Gender
Female 15 (18.3%) 3 (7.3%) 12 (3%) 0.011
Male 67 (81.7%)
†
38 (92.7%) 28 (70%)
Indigenous 3 (3.7%)
†
2 (4.9%) 1 (2.5%) –
Height (cm) 173 ± 9 175 ± 7 171 ± 10 0.129
Weight (kg) 89 ± 22 89 ± 19 90 ± 25 0.936
BMI 29 ± 6 29 ± 5 30 ± 7 0.674
LVEF (%) 29 ± 13 27 ± 8 31 ± 17 0.759
Cardiomyopathy type ICM: 41 (50%) 41 (50%) 40 (48.8%) 0.912







LV non compaction: 1
(1.2%)
Sarcoidosis: 1 (1.2%)
Hypertension 39 (47.6%) 23 (57.5%) 16 (42.1%) 0.275
Type 2 diabetes 24 (29.3%)
†
13 (32.5%) 11 (29%) 0.809
Hypercholesterolemia 58 (70.7%)
†
36 (90%) 22 (58%) 0.002
OSA 9 (11%) 0 (0%) 9 (23.7%) 0.001
Obesity 34 (41.5%) 19 (46.3%) 15 (38.5%) 0.506
Alcohol abuse 14 (17.1%) 4 (10%) 10 (26.3%) 0.079
COPD 15 (18.3%) 11 (27.5%) 4 (10.5%) 0.084
Smoking status
Current 9 (11 %) 6 (15%) 3 (7.9%) –
Former 25 (30.5%) 18 (45%) 7 (18.4%)
Unknown 5 (6.1%) 3 (7.5%) 2 (5.2%)
Atrial fibrillation
Chronic 9 (11%) 3 (7.3%) 6 (15.8%) –
PAF 26 (31.7%) 16 (39%) 10 (26.3%)
CABG
Primary 23 (28%) 23 (57.5%) 0 (0%) –
Redo 1 (1.2%) 1 (2.5%) 0 (0%)
PCI with stent
Single 5 (6.1%) 4 (40%) 1 (2.6%) –
x2 or more 8 (9.8%) 8 (20%) 0 (0%)
Valve replacement
Mitral 2 (2.4%) 2 (5%) 0 (0%) –
Aortic 3 (3.7%) 2 (5%) 1 (2.5%)
Data presented as total (%) or mean ± standard deviation.
†
p < 0.05. The patient with mixed indication was Male, Non-Indigenous, 166 cm, 77 kg, with a BMI of 31 and LVEF of 25%,
and the following comorbidities: Hypertension, Hypercholesterolemia, Obesity, COPD, Former smoker and PCI with single stent. ICM, Ischemic Cardiomyopathy; NICM, Non-Ischemic
Cardiomyopathy; BMI, Body Mass Index; LVEF, Left Ventricular Ejection Fraction; LV, Left Ventricle; HCM, Hypertrophic Cardiomyopathy; OSA, Obstructive Sleep Apnea; COPD, Chronic
Obstructive Pulmonary Disease; CABG, Coronary Artery Bypass Graft; AF, Atrial Fibrillation; PAF, Paroxysmal Atrial Fibrillation.
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RESULTS
Clinical Characteristics
The mean age of patients was 59 ± 16 years although the
NICM patient cohort was significantly younger (55 ± 18 years,
p=0.045). A significantly higher proportion of males received
ICDs in this district (81.7%; p=0.011). There was an even
distribution of ICM and NICM patients (50 vs. 48.8%, p= 0.912;
Table 2). Only three patients were identified as Indigenous. Risk
factors in our cohort included hypercholesterolemia (70.7%, p
< 0.05), hypertension (47.6%, p < 0.05), obesity (41.5%), and
Type 2 diabetes (29.3%) (Table 2). ICM patients had higher
hypercholesterolemia (90%; p = 0.002), higher smoking history,
coronary artery bypass grafting, valve surgery, and percutaneous
coronary intervention (Table 2). Severe obstructive sleep apnea
was found exclusively in the NICM group (23.7%, p = 0.001;
Table 2). Most patients received beta blockade medical therapy
(90.2%) with more ICM patients receiving statins (95.1%, p <
0.001) and antiplatelet (78%, p = 0.003) medications (Table 3).
Diuretics and ACE inhibitors were commonly prescribed, with
34.1% of all patients receiving an anticoagulant. Nitroglycerine
was more commonly prescribed in patients with coronary artery
disease (19.5%, p = 0.030) compared to those with a NICM
(Table 3).
The mean follow-up time following ICD implantation was 4.8
± 3 years (range: 0–13 years). New implants were received by
76.8% of patients and 20.7% had a generator change (Table 4).
ICDs included single chamber devices (40.2%) and dual (35.4%).
Cardiac resynchronisation therapy with defibrillation (CRT-D)
was fourfold higher in the NICM than ICM patients (12 vs. 3)
(Table 4).
Complications occurred in 13% of total patients (8 were ICM
and 3 NICM patients, p = 0.116; Table 5). Two patients had
lead revision, failed LV placement, and lead failure post-implant,
and one patient had an infection, lead perforation, wound
flush-and-clean and pre-implant arrest during the anesthetic
induction. Twenty-five patients (30.5%) died during the follow-
up period, with a mean survival time of 36.7 months (range:
26.4–47.1 months) (Figure 1). The ICM group had a 10-month
longer survival time compared to the NICM group (41.2 vs. 31.0
months) but this was not significant [Log Rank (Mantel Cox) χ2
= 1.393, df= 1, p= 0.238; Figure 2].
Risk Factors for Mortality and ICD Events
Age, gender, BMI, and ejection fraction were not significant
predictors of mortality in this patient population (Table 6).
Smokers were at a significantly higher risk of dying than non-
smokers (HR: 4.830, 95% CI: 1.229–18.985, p = 0.024; Table 6).
Aortic valve replacement carried a ∼12-fold increased risk of
death (p = 0.052) and mitral valve replacement a 4-fold risk
(p = 0.059; Table 6). Patients receiving two or more incidences
of inappropriate shocks were 18-fold more likely to die (HR:
18.286, 95% CI: 1.833–182.387, p= 0.013; Table 6). Interestingly,
patients who experienced complications had a 73% reduced risk
of mortality (HR: 0.275, 95%CI: 0.092–0.821, p= 0.021). Patients
with obstructive sleep apnea had a 70% reduced risk (Table 6).
Multivariate analysis of smoking history, inappropriate shocks,
and valve replacement surgery showed a significant increase in
mortality risk (χ2 = 17.601, df= 8, p= 0.024; Table 6).
Twenty-eight percent (n= 23) of all patients received therapy,
either pacing or defibrillation (Table 5). Almost 40% of NICM
patients received therapy compared to ∼20% of ICM patients (p
= 0.088). Of all patients who received therapy only 18.51% were
appropriate for sustained ventricular arrhythmias. While 22.5%
of NICM patients received appropriate therapy, 21.05% also
received inappropriate therapy, which was significantly higher
than in ICM patients (p = <0.001). Sudden cardiac death would
have occurred in three patients (3.7%), two ICM and one NICM
patient, if ICD defibrillation had not occurred (Table 5).
TABLE 3 | Medications for the study cohort.
Medication Total population ICM NICM P-value
Diuretics 57 (69.5%)
†
33 (80.5%) 24 (63.2%) 0.131
ACE 57 (69.5%)
†
31 (75.6%) 26 (70.2%) 0.619
Angiotensin 2 agonist 12 (14.6%) 8 (19.5%) 4 (10.5%) 0.353
B-blockers 74 (90.2%)
†
39 (95.1%) 35 (92.1%) 0.667
Ca-blockers 7 (8.5%) 5 (12.2%) 2 (5.3%) 0.434
Statins 60 (73.2%)
†
39 (95.1%) 21 (55.3%) <0.001
Insulin 10 (12.2%) 5 (12.2%) 5 (13.2%) 1.000
Non-insulin diabetic (Metformin/Diamicron) 15 (19.0%) 7 (17%) 8 (21%) 0.776
GTN 9 (11.0%) 8 (19.5%) 1 (2.63%) 0.030
Digoxin 20 (24.4%) 12 (29.3%) 8 (21.1%) 0.447
Antiplatelet 49 (59.8%)
†
32 (78%) 17 (44.7%) 0.003
Anticoagulant 28 (34.1%) 15 (36.6%) 13 (34.2%) 1.000
Amiodarone 9 (11%) 5 (12.2%) 4 (10.5%) 1.000
Data presented as total (%). Medications for the patient with mixed indication included a diuretic, ACE, statin, digoxin and antiplatelet. P-value represents between-groups difference.
†
p < 0.05. GTN, Nitroglycerine; ACE, Angiotensin Converting Enzyme.
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TABLE 4 | Device type and implant type for the primary prevention patients.
Parameter Total population ICM NICM P-value
Length of follow-up (years) 4.8 ± 3 (0–13) 4.8 ± 3 (1–13) 4.9 ± 3 (1–12) 0.954
Device type
Single chamber 33 (40.2%) 20 (49%) 12 (30%) –
Dual chamber 29 (35.4%) 16 (39%) 13 (32.5%)
PPM upgrade to dual chamber ICD 1 (1.2%) 1 (2.4%) 0 (0%)
PPM Upgrade to CRT-D 1 (1.2%) 0 (0%) 1 (2.4%)
Sub-Q ICD 3 (3.7%) 1 (2.4%) 2 (5%)
CRT-D 15 (18.3%) 3 (7.3%) 12 (30%)
Implant type
New implant 63 (76.8%)
†
33 (80.5%) 30 (75%) –
Generator change 17 (20.7%) 7 (17.1%) 9 (22.5%)
Generator change with new HV Lead 2 (2.4%) 1 (2.4%) 1 (2.5%)
Upgrade to CRT-D 3 (3.7%) 0 (0%) 3 (7.5%)
Downgrade to PPM 1 (1.2%) 1 (2.4%) 0 (0%)
CTS LV lead placement 1 (1.2%) 0 (0%) 1 (2.5%)
Data presented as total (%) or mean ± standard deviation (range) for length of follow-up. P-value represents between-groups difference.
†
p < 0.05. The patient with mixed indication
had CRT-D with CTS LV lead placement. ICM, Ischemic Cardiomyopathy; NICM, Non-Ischemic Cardiomyopathy; PPM, Permanent Pacemaker; ICD, Implantable Cardiac Defibrillator;
CRT-D, Cardiac Resynchronisation Therapy with Defibrillator; Sub-Q ICD, Subcutaneous Implantable Cardiac Defibrillator; PCI, Percutaneous Coronary Intervention; CTS, Coronary
Thoracic Surgery; LV, Left ventricle.
There were no significant associations between patient
demographics or risk factors and ventricular arrhythmias
(Table 7). However, if patients had a previous smoking history,
they were 2.7 times more likely to receive an appropriate shock
compared with patients who have never smoked (OR: 2.719, 95%
CI: 0.688–10.75, p = 0.154). Patients with hypercholesterolemia
also showed a two-fold increased likelihood of receiving therapy
for ventricular arrhythmias when compared to patients with
normal cholesterol levels (OR: 2.083, 95% CI: 0.592–7.327, p =
0.252; Table 7).
DISCUSSION
The management of ventricular arrhythmias in heart failure
patients remains challenging despite significant advances in
ICD innovation, clinical research and cardiovascular-modifying
drug therapies (7). We report that ICD patients serviced by
the Townsville University Hospital monitored over a 4.8-year
period had 30.5% all-cause mortality. We also report that 82%
(67 patients) experienced no sustained ventricular arrhythmias,
yet 28% (23 patients) received therapy. Eighteen per cent of
device therapy were appropriate and 14% were inappropriate.
No associations were found between ventricular arrhythmias and
ejection fraction, hypercholesterolemia, hypertension or obesity.
In NICM patients, sleep apnea was associated with a fourfold
increase in inappropriate shocks compared to ICM patients.
Interestingly, the overall risk of mortality was 73% lower in
patients who had complications, which may be due to increased
follow-up and medical care in this subset. Three patients would
have almost certainly died without an ICD. These data raise a
number of important questions about the utility and effectiveness
of ICDs and the current guidelines and selection criteria on who
should receive a device.
Mortality Was Higher in Regional North
Queensland
All-cause mortality of 30.5% in the Townsville district was 1.2 to
2 times higher than mortality reported in other cohort studies
in Australia, New Zealand, North America and Europe (15, 17–
20). Although we found no significant difference in mortality
between the ICM and NICM patients, the total mortality in ICM
patients was 1.4 to 2.4 times those in the MADIT, MADIT II,
and MUST trials (21, 22), and 1.3 to 2.8 times higher in the
NICM patients compared to the CAT, AMIOVIRT, DEFINITE,
and recent DANISH trials (23–26).
Currently, we do not know the reasons for the higher
mortality but it may relate to differences in patient inclusion
and exclusion criteria. For example, in contrast to the CAT,
DEFINITE and DANISH trials, we did not exclude patients
with valvular disease, those on anti-arrhythmics, or permanent
atrial fibrillation patients, respectively (23, 25, 26). Increased
mortality in our patient cohort may also be related to heart
failure progression in our cohort or the type and severity
of comorbidities (27). Cardiovascular disease, for example, is
responsible for 30% more hospitalizations in outer regional
and rural centers than urban centers. Age did not appear to
be a factor (Table 2), which was different from many other
published studies (15, 17, 18, 20). The possible role of regional,
rural and urban health inequities to higher mortality requires
further investigation.
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TABLE 5 | Mortality, procedural complications, and therapy following implant.
Parameter Total population ICM NICM P-value
Time to mortality (months)
†
32 (7–103) 40 (7–103) 23 (7–96) 0.267
Total complications 11 (13.3%) 3 (7.3%) 8 (20%) 0.116
Complications
• Lead revision
2 (2.4%) 0 (0%) 2 (5%) –
• Infection 1 (1.2%) 0 (0%) 1 (2.5%)
• Failed LV placement 2 (2.4%) 1 (2.4%) 1 (2.5%)
• Lead perforation 1 (1.2%) 0 (0%) 1 (2.5%)
• Wound flush and clean 1 (1.2%) 0 (0%) 1 (2.5%)
• Lead failure post-implant 2 (2.4%) 1 (2.4%) 1 (2.5%)
• Pre-implant arrest during anesthetic induction 1 (1.2%) 1 (2.4%) 0 (0%)





Appropriate therapy (ATP and Shocks) 15 (18.5%) 6 (14.6%) 9 (22.5%) 0.387
12 (Single chamber) 6 DCM (15%)
3 (Dual chamber) 1 HCM (2.5%)
1 Sarcoidosis (2.5%)
1 Channelopathy (2.5%)
Inappropriate therapy (ATP and Shocks) <0.001
• AF/SVT 10 (12.6%) 3 (7.3%) 7 (18.4%)
4 (Single chamber) 0 (0%) 5 DCM (12.5%)
6 (Dual chamber) 2 HCM (5%)
• Lead malfunction 1 (1.3%) 1 (2.6%)
1 (Dual chamber) 1 DCM (2.6%)
Number of shocks in lifetime
†
0 (0–55) 0 (0–55) 0 (0–18) 0.089









• Appropriate VT 3 (3.7%) 1 (2.4%) 2 (5.3%) –
2 DCM (5.3%)
• Appropriate VF 2 (2.4%) 1 (2.4%) 1 (2.6%)
1 Channelopathy (2.6%)
1 (1.2%) 1 (2.4%) 0 (0%)
• VT storm 8 (9.8%) 2 (4.9%) 6 (15.8%)
• Inappropriate x1 4 DCM (10%)
2 HCM (5%)
2 (2.4%) 0 (0%) 2 (5.3%)
• Inappropriate x2 or more 2 DCM (5.3%)
Number of ATP in lifetime
†
0 (0–167) 0 (0–167) 0 (0–13) 0.305
Anti-tachycardia pacing 0.001




2 (2.4%) 1 (2.4%) 1 (2.6%)
Inappropriate 1 DCM (2.6%)
Sudden cardiac death criteria (VT/VF >240 bpm) 3 (3.7%) 2 (4.9%) 1 (2.5%)
1 Channelopathy (2.5%)
0.571
Data presented as total (%) or median (range)
†
. ICM, Ischemic Cardiomyopathy; NICM, Non-Ischemic Cardiomyopathy; BMI, Body Mass Index; LVEF, Left Ventricular Ejection Fraction;
LV, Left Ventricle; HCM, Hypertrophic Cardiomyopathy; DCM, Dilated Cardiomyopathy; VT, Ventricular Tachycardia; VF, Ventricular Fibrillation; AF, Atrial Fibrillation; SVT, Supraventricular
Tachycardia; ATP, Anti-tachycardia Pacing; Single chamber device; Dual chamber device.
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FIGURE 1 | Kaplan–Meier survival analysis of the total patient population receiving ICDs in the Townsville District from January 2008–December 2015. Twenty-five
patients died during the follow-up period as represented by the events on the Kaplan-Meier cumulative survival curve.
FIGURE 2 | Kaplan–Meier survival analysis of the ICM and NICM patient cohorts in the Townsville District over 4.8-years follow-up from January 2008–December
2015. Log rank test shows no significant difference in survival between ICM and NICM patients (p = 0.238). ICM, ischemic cardiomyopathy; NICM, non-ischemic
cardiomyopathy.
Only 19% of Patients Received Appropriate
ICD Therapy
Of the 82 patients implanted with an ICD only 15 received
appropriate pacing/shock therapy. On face value 18% appears to
be a low success rate. However, in our study 67 patients did not
experience ventricular arrhythmias over the duration of 4.8 years,
which needs to be taken into consideration when determining a
therapy’s success rate. An appropriate therapy rate of 18% sits at
the lower end of the published range of 11.6 to 24% over 2.1–3.64
years follow-up (11, 15, 19, 20, 28–31). In a large randomized
control trial of 2,521 patients Bardy showed a 21% appropriate
shock rate in the ICD arm (32, 33). However, many of these
studies don’t report the percentage of patients who did not have
sustained ventricular arrhythmias. A unique and distinguishing
feature of our study was its analysis of intracardiac electrograms
allowing such determinations.
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TABLE 6 | Cox proportional hazard model for predictors of mortality.
Variable Hazard ratio (95% CI) P-value
Female gender 0.918 (0.236–3.129) 0.891
Age 0.993 (0.948–1.039) 0.748
BMI 1.028 (0.971–1.088) 0.342
LVEF% 1.007 (0.955–1.061) 0.799
ATP in life-time 0.993 (0.980–1.007) 0.318







CABG 0.387 (0.046–3.224) 0.380
Hypertension 1.489 (0.583–3.806) 0.406
Diabetes 1.327 (0.583–3.021) 0.500
Hypercholesterolemia 1.199 (0.352–4.092) 0.772
OSA 0.301 (0.080–1.141) 0.077
Obesity 0.626 (0.265–1.483) 0.287
Alcohol abuse 0.804 (0.262–2.468) 0.703
COPD 1.250 (0.458–3.413) 0.663




Any AF 0.806 (0.351–1.851) 0.611
Chronic AF 0.863 (0.356–2.092) 0.774








CI, confidence interval; BMI, body mass index; LVEF, left ventricular ejection fraction;
ATP, Anti-tachycardia pacing; CABG, cardiopulmonary bypass graft; OSA, obstructive
sleep apnea; COPD, chronic obstructive pulmonary disease; AF, atrial fibrillation. Results
represent univariate analysis. Multivariate analysis was conducted using variables “Current
Smoker” and “Inappropriate Therapy (x2 or >)” which showed significantly increased
hazard ratio for mortality, as well as “Mitral Valve Replacement” and “Aortic Valve
Replacement,” which approached statistical significance (p = 0.052 and p = 0.059,
respectively).
†
Multivariate analysis: χ2 = 17.601, df = 8, p = 0.024.
Inappropriate ICD Therapy Was Associated
With Poor Outcomes
We also found in our study that eleven patients (14%) received
inappropriate therapy. This subset included 10 patients who
had not experienced ventricular arrhythmias and one patient
who had an arrhythmia. From our electrocardiogram analysis,
inappropriate device therapy was also delivered in response
to supraventricular tachycardias (Table 5). The inability of the
device to distinguish between ventricular and atrial arrhythmias
appears to be related to ICD programming and algorithms of
rate parameters and detection times (34). This is an important
area of future ICD development for primary prevention of
sudden cardiac death because, in our study, those patients who
received two or more inappropriate shocks were 18 times more
likely to die than those who received only one event or no
inappropriate therapy (Table 6). In a larger study, Van Rees
similarly showed that inappropriate shock therapy was related to
a 1.6-fold increase risk of mortality (35).
TABLE 7 | Univariate binary logistic regression for appropriate therapy.
Variable Odds ratio (95% CI) P-value
Female gender 1.425 (0.340–5.970) 0.628
Age 0.995 (0.960–1.032) 0.798
Hypertension 0.831 (0.252–2.743) 0.760
Diabetes 1.000 (0.275–3.634) 1.000
Hypercholesterolemia 2.083 (0.592–7.327) 0.253
OSA 1.684 (0.192–14.752) 0.638
BMI 1.039 (0.947–1.141) 0.418
Obesity 0.838 (0.254–2.763) 0.771
Alcohol abuse 1.245 (0.244–6.367) 0.792
COPD 1.375 (0.271–6.980) 0.701
Ever smoked 2.719 (0.688–10.751) 0.154
AF 0.632 (0.191–2.086) 0.451
LVEF % 1.024 (0.983–1.067) 0.257
Complications 0.825 (0.157–4.346) 0.820
CI, confidence interval; OSA, obstructive sleep apnea; BMI, body mass index; COPD,
chronic obstructive pulmonary disease; AF, atrial fibrillation; LVEF, left ventricular
ejection fraction.
NICM Patients had Significantly Higher
Inappropriate Shocks
Another standout finding from the above analysis was the higher
rate of inappropriate shock therapy delivered to NICM patients
(20%) compared to ICM patients (4.9%; p= 0.039). This suggests
that our NICM patients were predisposed to higher incidences
of supraventricular or atrial arrhythmias. This group also had
significantly higher incidence of obstructive sleep apnea (OSA)
(23.7%) than ICM patients (0%) (p = 0.001). This is interesting
because sleep apnea is strongly associated with atrial fibrillation
(36), and was a predictor of inappropriate shocks in the study
of Fernandez-Cisnal (30). Kreuz et al. also reported that ICD
patients with sleep disorders had two times the inappropriate
therapy of those without sleep apnea (37). Unfortunately, we
did not examine the association between atrial fibrillation and
sleep apnea throughout the 4.8-year follow-up. Why primary
prevention NICM patients are more vulnerable to inappropriate
shocks than ICM patients requires further investigation (26, 38).
In addition, there is an urgent need to clarify heart failure
guidelines for this vulnerability in NICM patients (4, 39).
Risk/Benefit and Cost Considerations of
ICD Implantation
Considering that 82% of total patients did not have sustained
ventricular arrhythmias over the 4.8-year period, our study,
although small, raises ethical questions about the pros and
cons of having a device implanted, and validity of current ICD
selection criteria. Notwithstanding, the life-saving potential of
having a device, the clinical criteria for deciding who needs a
primary prevention ICD is imprecise (8, 14, 40). Notwithstanding
these important issues, three patients would have likely died
without their ICD (Table 5). Healthcare costs are another
consideration. The average procedural cost for ICD implantation
in Australia is ∼$22,000 (without complications), and $47,000
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(with complications) (3, 41). In the Townsville district, the cost
to healthcare providers for the 67 patients who did not need a
device (no sustained ventricular arrhythmias) is estimated to be
at least $1.5M, and if our data is representative of other centers in
Australia, the national savings could be 82% of $155M per year
(2011–2014) or $127M per annum (41).
Limitations of the Study
A limitation of the present study was that it was a retrospective,
observational analysis on a small population at a single center,
regional tertiary hospital, that included both new implants and
generator changes. A larger population of primary prevention
ICD patients including more hospitals and service areas in
Northern Australia, and a comparator from an urban center,
would provide more information on the different rates of
outcomes and to better evaluate this regional area compared to
larger hospitals in metropolitan centers. Another limitation was
that there was no analysis of ECGs performed in the patients
who received appropriate shocks prior to implant which may
have contributed to a more detailed assessment of a patient’s risk.
This is a topic of future research. Lastly, a detailed cost-effective
analysis would provide important data to inform providers to the
benefit and health-related quality of life of ICD recipients.
Conclusions
Primary prevention ICD patients implanted at the Townsville
University Hospital had high rates of mortality and low
rates of sustained ventricular arrhythmias. The incidence of
inappropriate ICD therapy was comparable to appropriate
therapy, and was associated with increased mortality.
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